High-purity CYP17 inhibitor API for advanced prostate cancer formulation manufacturing.
Abiraterone Acetate API is a potent, selective, and irreversible inhibitor of cytochrome P450 17A1 (CYP17), a critical enzyme in androgen biosynthesis. It is used to treat metastatic castration-resistant prostate cancer (mCRPC). This API is manufactured in a fully cGMP-compliant facility and is available as a crystalline powder with full USDMF documentation.